UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

Annals of oncology, 2015-07, Vol.26 (7), p.1333-1340

2015

Volltextzugriff (PDF)

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

British journal of cancer, 2006-03, Vol.94 (6), p.798-805

2006

Volltextzugriff (PDF)

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333–1340

Annals of oncology, 2020-03, Vol.31 (3), p.444-445

2020

Volltextzugriff (PDF)

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

Annals of oncology, 2016-10, Vol.27 (10), p.1873-1878

2016

Volltextzugriff (PDF)

The role of bevacizumab plus front-line chemotherapy in patients with malignant ascites of ovarian cancer

Annals of oncology, 2018-10, Vol.29, p.viii348-viii348

2018

Volltextzugriff (PDF)

Prevention and prophylaxis of thrombosis in cancer patients

Annals of oncology, 2018-10, Vol.29, p.viii614-viii614

2018

Volltextzugriff (PDF)

A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer

Cancer chemotherapy and pharmacology, 2016-05, Vol.77 (5), p.949-956

2016

Volltextzugriff (PDF)

Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

Cancer chemotherapy and pharmacology, 2016-08, Vol.78 (2), p.369-376

2016

Volltextzugriff (PDF)

Metabolic syndrome and Cancer: Do they share common molecular pathways?

Forum of clinical oncology, 2016-06, Vol.7 (2), p.7-15

2016

Volltextzugriff (PDF)

Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature

Endocrine, 2010-02, Vol.37 (1), p.6-10

2010

Volltextzugriff (PDF)

1818MO Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? Intermediate results from the MeTHOS study

Annals of oncology, 2020-09, Vol.31, p.S1049-S1050

2020

Volltextzugriff (PDF)

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

Annals of oncology, 2020-03, Vol.31 (3), p.444-445

2020

Volltextzugriff (PDF)

1181P Real-world data on neuroendocrine neoplasms (NENs): Preliminary results of an observational study by the Hellenic Society of Medical Oncology (HeSMO)

Annals of oncology, 2020-09, Vol.31, p.S780-S780

2020

Volltextzugriff (PDF)

977PThe role of bevacizumab plus front-line chemotherapy in patients with malignant ascites of ovarian cancer

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?

Journal of B.U. ON., 2010-10, Vol.15 (4), p.791

2010

Volltextzugriff (PDF)

Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy

Oncology, 2008-01, Vol.74 (1-2), p.31-36

2008

Volltextzugriff (PDF)

Surgical options in cases of tumorous destruction of the proximal humerus: twenty-one patients followed from 4-9 years

Journal of B.U. ON., 2009-01, Vol.14 (1), p.57

2009

Volltextzugriff (PDF)

Resection versus resection combined with adjuvant pre- and post-operative chemotherapy--immunotherapy for metastatic colorectal liver cancer. A new look at an old problem

Hepato-gastroenterology, 1995-04, Vol.42 (2), p.155

1995

Volltextzugriff (PDF)

Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome

Journal of B.U. ON., 2010-10, Vol.15 (4), p.647

2010

Volltextzugriff (PDF)

1719PPrevention and prophylaxis of thrombosis in cancer patients

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma

Journal of B.U. ON., 2009-07, Vol.14 (3), p.507

2009

Volltextzugriff (PDF)

Abstract P1-12-02: Sequential versus concurrent administration of epirubicin and docetaxel as adjuvant chemotherapy in women with high-risk axillary lymph node negative early breast cancer. An interim analysis of a multicenter randomized study from the Hellenic oncology research group

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-12-02

2016

Volltextzugriff (PDF)

Should patients with active urological cancers receive thromboprophylaxis for Cancer Associated Thrombosis (CAT)?

European urology open science (Online), 2021-11, Vol.33, p.S417-S418

2021

Volltextzugriff (PDF)

Abstract P1-13-09: A multicenter randomized study comparing the dose dense G-CSF-supported sequential administration of FEC followed by docetaxel versus paclitaxel as adjuvant chemotherapy in women with axillary lymph node positive breast cancer

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P1-P1-13-09

2012

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(57)

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333–1340

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

The role of bevacizumab plus front-line chemotherapy in patients with malignant ascites of ovarian cancer

Prevention and prophylaxis of thrombosis in cancer patients

A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer

Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

Metabolic syndrome and Cancer: Do they share common molecular pathways?

Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature

1818MO Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? Intermediate results from the MeTHOS study

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

1181P Real-world data on neuroendocrine neoplasms (NENs): Preliminary results of an observational study by the Hellenic Society of Medical Oncology (HeSMO)

977PThe role of bevacizumab plus front-line chemotherapy in patients with malignant ascites of ovarian cancer

Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?

Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy

Surgical options in cases of tumorous destruction of the proximal humerus: twenty-one patients followed from 4-9 years

Resection versus resection combined with adjuvant pre- and post-operative chemotherapy--immunotherapy for metastatic colorectal liver cancer. A new look at an old problem

Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome

1719PPrevention and prophylaxis of thrombosis in cancer patients

Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma

Abstract P1-12-02: Sequential versus concurrent administration of epirubicin and docetaxel as adjuvant chemotherapy in women with high-risk axillary lymph node negative early breast cancer. An interim analysis of a multicenter randomized study from the Hellenic oncology research group

Should patients with active urological cancers receive thromboprophylaxis for Cancer Associated Thrombosis (CAT)?

Abstract P1-13-09: A multicenter randomized study comparing the dose dense G-CSF-supported sequential administration of FEC followed by docetaxel versus paclitaxel as adjuvant chemotherapy in women with axillary lymph node positive breast cancer

Aktive Filter

Suchergebnisse filtern